BBH250117C157000
- 0.00
- 0.000.00%
VanEck Biotech ETF Newsroom
The Analyst Verdict: Natera In The Eyes Of 14 Experts
Forecasting The Future: 22 Analyst Projections For Regeneron Pharmaceuticals
Gilead Upgraded by Morgan Stanley on Lenacapavir Potential
Forecasting The Future: 23 Analyst Projections For Vertex Pharmaceuticals
This McDonald's Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
4D Molecular, FDA Agree on Phase 3 Design for DME Candidate
Vertex Pharmaceuticals Analyst Ratings
Pfizer Is 'Too Low To Sell,' Jim Cramer Says: Recommends Nvidia For Robotics Exposure
Gilead Sciences Analyst Ratings
Pharma Companies Welcome New Year With 583 Drug Price Hikes so Far
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
Drugs Not Selected for Medicare Price Negotiation Nearly Doubled - Report
Novo, Eli Lilly to Dominate Global Pharma Sales in 2025: Report
Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus
Merck Downgraded by Truist to Hold Over Growth Concerns
Asher Bio Announces Clinical Trial Collaboration And Supply Agreement With Amgen On Etakafusp Alfa In Combination With Bispecific T-cell Engager In Patients With Small Cell Lung Cancer
ICON Plc Released The Findings Of A Survey Of Over 120 Biotech And Pharma Professionals Developing Treatments For Neurodegenerative Disorders
Compugen Announced That The First Patient Was Dosed In A Phase 1 Clinical Trial With Com503, A Potential First-in-class Antibody Against Il-18 Binding Protein Licensed By Compugen To Gilead
Amgen Analyst Ratings
ICON Plc Draws Bullish Views at RBC on Attractive Valuation